ClearPoint Neuro, Inc. — News

ClearPoint Neuro (NASDAQ: CLPT) reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies intended to support commercial-scale neuro drug delivery. Total revenue for the three months ended June 30 was $10.9 million, up 18% from $9.2 million in the prior-year period, CFO Danilo D'Alessandro said.

defenseworld.net - 2026-08-05 03:09:30

ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.

seekingalpha.com - 2026-08-04 17:10:20

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

seekingalpha.com - 2026-08-04 03:30:05

The headline numbers for ClearPoint Neuro (CLPT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-08-03 20:01:03

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.21 per share a year ago.

zacks.com - 2026-08-03 19:46:20

ClearPoint Neuro NASDAQ: CLPT reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies intended to support commercial-scale neuro drug delivery.

marketbeat.com - 2026-08-03 18:04:48

Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Highlights Reported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue declined 15% in the quarter, primarily due to a decrease in products shipped to biopharma customers supporting new trial initiations compared to the second quarter a year ago.

accessnewswire.com - 2026-08-03 16:05:00

RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulated its partner Aspen Neuroscience, Inc. on receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), Aspen's investigational autologous dopaminergic neuron cell replacement therapy for Parkinson's disease.

accessnewswire.com - 2026-07-31 16:05:00

SOLANA BEACH, CA / ACCESS Newswire / July 21, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2026 second quarter on Monday, August 3rd, after the market close. Investors and analysts are invited to listen to the live broadcast review of the Company's 2026 second quarter on Monday, August 3rd at 4:30 p.m.

accessnewswire.com - 2026-07-21 16:05:00

ClearPoint Neuro remains a speculative Buy, offering leveraged exposure to gene therapy commercialization and neurosurgery navigation growth. Recent FDA feedback on uniQure's AMT-130 renews optimism for near-term revenue, but regulatory and partner execution risks persist. CLPT's Q1 organic growth slowed, cash burn accelerated, and full-year 2026 revenue guidance ($52–$56M) disappointed versus expectations.

seekingalpha.com - 2026-06-18 08:30:44

ClearPoint Neuro (CLPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

zacks.com - 2026-06-18 07:41:05

Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including both focused ultrasound hardware and ClearPoint Navigation Software and Robotics SOLANA BEACH, CA / ACCESS Newswire / May 27, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced plans to enter the focused ultrasound market, and demonstrated successful intravenous delivery of tracers across the blood-brain barrier in a preclinical model using the ClearPoint prototype system. This device was built in partnership with the SONOCARELAB, at Sungkyunkwan University in Suwon, South Korea on the Natural Science Campus.

accessnewswire.com - 2026-05-27 16:30:00

ClearPoint Neuro, Inc. (CLPT) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-13 20:40:43

Although the revenue and EPS for ClearPoint Neuro (CLPT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com - 2026-05-13 19:00:25

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.22 per share a year ago.

zacks.com - 2026-05-13 18:36:15

ClearPoint Neuro NASDAQ: CLPT reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management highlighted growth in its legacy neurosurgical device business and early contributions from the recently acquired IRRAflow product line.

marketbeat.com - 2026-05-13 18:06:14

Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Highlights Reported first quarter revenue of $12.1 million, including $2.3 million of IRRAflow revenue, representing 43% overall growth and 16% year-over-year total organic growth compared with the first quarter of 2025; The activated installed base across all ClearPoint technology including IRRAflow systems now includes over 175 global centers; Achievement of measurable revenue and cost synergies through the continuing integration of the IRRAflow product portfolio and team; Continued clinical trial and regulatory progress across more than 60 active biopharma partners; FDA clearance and successful completion of the first clinical procedure utilizing the Velocity Alpha MR High Speed Surgical Drill System; Received Medical Device License (MDL) from Health Canada for the ClearPoint Neuro Navigation System, covering both MRI-guidance and iCT guidance workflows with first cases now scheduled; Completion of the first commercial drug delivery case utilizing ClearPoint technology in the Asia-Pacific region; Gross margin expanded to 64%; and Reported cash and cash equivalents totaling $35.6 million as of March 31, 2026.

accessnewswire.com - 2026-05-13 16:05:00

SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that the Velocity Alpha ® MR High Speed Surgical Drill System has received CE Marking in addition to the existing FDA 510(k) clearance in the United States. The Velocity Alpha MR High Speed Surgical Drill System is manufactured by German-based surgical equipment leader Adeor Medical AG.

accessnewswire.com - 2026-05-13 16:00:00

Pre-Market Stock Futures: Futures are trading higher as we get set to end what has been one of the wildest weeks on Wall Street in some time. After blowing through all-time highs for the umpteenth time on Wednesday, stocks started higher again on Thursday but started to sell off after the noon hour. While most... Here Are Friday's Top Wall Street Analyst Research Calls: Applied Materials, Devon Energy, Epam Systems, HubSpot, Nike, Shake Shack, Tapestry, Qualcomm, and More

247wallst.com - 2026-05-08 08:06:45